The network meta-analysis revealed a statistically significant superiority of SGLT2 inhibitors over GLP-1 receptor agonists in preventing heart failure-related hospitalization (HR = 0.75, 95% CI = 0.66-0.85). The gene discussed is GLP1R; the disease is heart failure.